Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Applied Therapeutics (APLT) EBT Margin (2023 - 2025)

Historic EBT Margin for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to 1661.4%.

  • Applied Therapeutics' EBT Margin rose 216058100.0% to 1661.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 9631.2%, marking a year-over-year decrease of 540894100.0%. This contributed to the annual value of 22146.15% for FY2024, which is 215140800.0% down from last year.
  • Applied Therapeutics' EBT Margin amounted to 1661.4% in Q3 2025, which was up 216058100.0% from 23267.21% recorded in Q3 2024.
  • In the past 5 years, Applied Therapeutics' EBT Margin ranged from a high of 3096.85% in Q4 2023 and a low of 23267.21% during Q3 2024
  • For the 3-year period, Applied Therapeutics' EBT Margin averaged around 7657.23%, with its median value being 5957.45% (2025).
  • In the last 5 years, Applied Therapeutics' EBT Margin crashed by -101537200bps in 2024 and then surged by 216058100bps in 2025.
  • Applied Therapeutics' EBT Margin (Quarter) stood at 3096.85% in 2023, then tumbled by -851bps to 23267.21% in 2024, then skyrocketed by 93bps to 1661.4% in 2025.
  • Its last three reported values are 1661.4% in Q3 2025, 23267.21% for Q3 2024, and 13758.33% during Q2 2024.